Search results
Found 57 matches for
The BioEscalator is delighted to welcome Spectre Bio to its start-up community. The company joins us as it transitions from computational research to laboratory-based development, bringing an exciting new immunomodulatory platform to the BioEscalator ecosystem.
Akimbo Bio crosses the bridge from academia to industry as it joins the BioEscalator
3 December 2025
The BioEscalator is pleased to welcome Akimbo Bio to its community of innovative bioscience start-ups. Co-founded by two Oxford researchers, the company is developing a next-generation immunotherapy platform that leverages intelligent receptor crosstalk to enhance both the efficacy and safety of cancer treatments.
Spectre Bio moves from computation to the lab as it joins the BioEscalator
3 December 2025
The BioEscalator is delighted to welcome Spectre Bio to its start-up community. The company joins us as it transitions from computational research to laboratory-based development, bringing an exciting new immunomodulatory platform to the BioEscalator ecosystem.
Icosphere Biosciences appoints Dr John Beadle as Non-Executive Director
27 November 2025
Dr Beadle brings a remarkable track record of leading biotechnology companies, guiding teams from early discovery through to successful clinical translation.
U-Ploid Biotechnologies wins Femtech competition award at the Carlos Simón Foundation for research in women’s health
21 November 2025
U‑Ploid, a biotechnology company developing first-in-class therapeutics to tackle age-related infertility, has been awarded the Femtech Competition Award at the Femtech Pitch Showcase & Competition organised by the Carlos Simón Foundation for Research in Women’s Health, a leading institution advancing scientific excellence in reproductive medicine.
Oxford Cancer Analytics secures new space at Inventa to accelerate diagnostic innovation
18 November 2025
Oxford Cancer Analytics (OXcan), a fast-scaling diagnostics company, has committed to a new lease of 2,400 square feet at Mission Street and BGO’s Inventa building in Oxford’s West End. OXcan is continuing its growth trajectory, moving from the BioEscalator to Inventa and joining a growing number of innovation companies in the emerging central cluster.
U-Ploid presents first Lyvanta™ data demonstrating reduction of aneuploidy in aged oocytes at ASRM 2025
27 October 2025
U-Ploid is today presenting its first scientific abstract, “Preclinical testing of a novel therapeutic for reduction of aneuploidy in oocytes,” at the 2025 American Society for Reproductive Medicine (ASRM) Annual Meeting in San Antonio, Texas. The study showcases preclinical data on Lyvanta™ (UP-085), a novel therapeutic designed to reduce chromosome segregation errors in oocytes associated with maternal age.
Exogene Graduates from the BioEscalator
15 October 2025
We are delighted to celebrate the graduation of Exogene as it transitions from the BioEscalator to its new home at the Wood Centre for Innovation.
Simon Meier will be joining Oxford Cancer Analytics (OXcan) as Incoming Interim CEO
14 October 2025
Simon brings over two decades of strategic leadership and investment expertise across diagnostics, biotech, and digital health innovation.
Dr. Peter Jianrui Liu to step down as CEO of Oxford Cancer Analytics Ltd (OXcan)
10 October 2025
Dr. Peter Jianrui Liu, Co-Founder of OXcan, has decided to step down from his role as the Company’s Founding CEO, to pursue other interests. He will remain a significant shareholder in the Company and therefore will retain every interest in the Company’s development and success as an advisor.
Oxford Cancer Analytics featured in CTV News
12 September 2025
In the piece, CEO and co-founder Dr. Peter Jianrui Liu shares how the company is pioneering a non-invasive blood test for the early detection of lung cancer, using proteomics and AI/ML. Oxford Cancer Analytics' technology aims to change the way cancers are diagnosed, detecting disease earlier, cutting costs for health systems, and most importantly, saving lives.
Green is the new gold: Infinitopes awarded gold LEAF accreditation
21 August 2025
Infinitopes has achieved the gold standard among the latest awardees for the Laboratory Efficiency Assessment Framework (LEAF), an innovative initiative to improve laboratory efficiency. As the second BioEscalator tenant to earn this accreditation, they follow in the footsteps of 2023/24 winner, Exogene.
Congratulations Alethiomics, the BioEscalator’s most recent graduate
19 August 2025
We’re proud to celebrate the graduation of Alethiomics, a University of Oxford spin-out dedicated to developing innovative treatments for blood cancers, as they move from the BioEscalator to their new home at Abingdon Science Park.
Innovate UK awards Icosphere Biomedical Catalyst grant
19 August 2025
Icosphere Biosciences Awarded Innovate UK Biomedical Catalyst Grant to Develop Breakthrough Gene Therapy Vector Manufacturing Technology.
Innovate UK feature Infinitopes in recent case study
6 August 2025
Infinitopes received Innovate UK funding through the Investor Partnership Programme, which was pivotal to building and testing their cutting-edge discovery platform, and the Cancer Therapeutics Programme, to design, prepare and execute its phase I clinical trial, that scientists hope will be practice-changing.
U-Ploid Biotechnologies featured in EQT Foundation's 25 Scientific Founders Pushing the Frontiers of Impact 2025 report
27 July 2025
U-Ploid Biotechnologies is rewriting the script on fertility treatments, tackling the root cause of age-related egg decline with groundbreaking science.
Welcome, Sandbox Bioscience, to the BioEscalator Community!
22 May 2025
We are excited to announce that Sandbox Bioscience, an ambitious biotech start-up founded by a team of virology experts from the Oxford ecosystem, has joined the BioEscalator.
U‑Ploid Biotechnologies selected for prestigious Merck Corporate Accelerator Programme to advance women’s health innovation
1 May 2025
U‑Ploid, a biotechnology company developing first-in-class therapeutics to address age-related infertility, today announced its selection for the inaugural Merck Corporate Accelerator. The programme, launched by EMD Serono in partnership with the Society for Innovation and Startups (SIS), is designed to support breakthrough innovation in women’s health by providing funding, expert mentorship, and access to Merck’s global network of scientific and clinical leaders.
Infinitopes granted Phase I/IIa Clinical Trial Application approval to evaluate precision vaccine targeting early-stage oesophageal cancer
8 April 2025
Infinitopes Ltd today announces that the UK Medicines and Healthcare products RegulatoryAgency (MHRA) has granted Clinical Trial Application (CTA) approval for the first-in-humanPhase I/IIa clinical trial of ITOP1, the company’s lead ‘off-the-shelf’ cancer vaccine. ITOP1 is a precision cancer vaccine, designed to safely and accurately target tumour antigens, leveraging the company’s vector delivery system, aiming to drive strong and durable T-cell protection for patients with surgically resectable oesophageal adenocarcinoma (OAC).
Care Fertility and U-Ploid Biotechnologies announce research collaboration to improve egg quality in women of advanced maternal age
7 April 2025
Care Fertility, a leading fertility treatment provider, and U-Ploid Biotechnologies, a pioneering reproductive health biotech, today announces a research collaboration aimed at improving egg quality and improve fertility treatment. Egg quality is one of the main contributing factors to infertility and is known to deteriorate rapidly with increasing female age. This research collaboration has the potential to validate novel therapeutics and offer hope to millions struggling to conceive.
Dr Mary Vinson joins the U-Ploid as Clinical Development Advisor
5 April 2025
Dr Vinson brings over 25 years of invaluable experience in the pharma and biotech industry, with a proven track record of leading and contributing to breakthrough therapeutics.